Fundraising FoxPhytonix
Black Mountain, US · 1 known investors
Find your way into Phytonix
Each arrow is one introduction. Sign up to fill in the first one.
455 people can intro you to Bruce
Ask James Vance to introduce you to Bruce Dannenberg
You →James · together at Western Southern Financial Group →Bruce
Sign up to find every way you can get introduced to Phytonix
- Your email: who you already know at Phytonix, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Phytonix team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Phytonix is an industrial biotechnology company that uses genetically engineered cyanobacteria and synthetic biology to convert carbon dioxide emissions and sunlight into sustainable chemicals and fuels, starting with n-butanol as a drop-in gasoline replacement and industrial chemical. It targets the global n-butanol chemical market and co-locates its production with industrial CO2 emitters.
Founders & leadership
BD
Bruce DannenbergFounderBruce Dannenberg founded Phytonix Corporation, an industrial biotechnology company developing cyanobacterial platforms to produce chemicals and fuels from carbon dioxide and sunlight. He brings experience in R&D operations, biochemical process development, intellectual property strategy, and business development from work with multinational companies.
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.1M disclosed across 2 of 4 rounds · 2015–2021
▶$8KraisedAug 2021 · 1 investors · Other EnergyRule 506(b)
▶$8KraisedAug 2021 · 1 investors · Other Energy
Rule 506(b)Officers, directors & promoters on the filing
- Michael WeedonDirector
- Bruce DannenbergExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $8K
- Minimum investment
- $7K
- Proceeds to insiders
- $50K
- First sale
- Aug 2021
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$3MofferedSep 2019 · Other EnergyRule 506(b)
▶$3MofferedSep 2019 · Other Energy
Rule 506(b)Officers, directors & promoters on the filing
- Gordon Dennis SkeneExecutive Officer, Director
- William H CoryDirector
- Michael WeedonDirector
- Bruce DannenbergExecutive Officer, Director
- Rick HoppDirector
- Offering amount
- $3M
- Minimum investment
- $10K
- Proceeds to insiders
- $320K
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$3MraisedSep 2018 · 112 investors · Other EnergyRule 506(b)
▶$3MraisedSep 2018 · 112 investors · Other Energy
Rule 506(b)Officers, directors & promoters on the filing
- Rick HoppDirector
- Bruce DannenbergExecutive Officer, Director
- Michael WeedonDirector
- Gordon Dennis SkeneExecutive Officer, Director
- William H CoryDirector
- Offering amount
- $3.8M
- Amount sold
- $3M
- Minimum investment
- $10K
- Proceeds to insiders
- $896K
- First sale
- Feb 2015
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Tonix Pharmaceuticals HoldingTonix is a biotechnology company developing therapies for chronic and complex conditions across central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. Its pipeline includes candidates for acute stress disorder, PTSD, smallpox/mpox vaccination, organ transplant rejection, and Prader-Willi syndrome.
NanoionixNanoionix develops EcoCer, a class of permanent, self-disinfecting ceramic materials and coatings that continuously inactivate bacteria, viruses, fungi, and algae without leaching into the environment. The coatings can be applied to metal, plastic, glass, ceramic, textile, wood, and paper during manufacturing or as an aftermarket treatment.
CytonicsCytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.
Thumbnail for SyntheXSyntheX develops the ToRFLEx platform, a first-in-class drug discovery technology that enables screening for compounds that modulate protein-protein interactions and targeted protein degradation for previously inaccessible drug targets identified by geneticists. The company builds an internal oncology pipeline and partners with external organizations to expand adoption of its platform.
Companies working in the same space as Phytonix.
Frequently asked questions
- What does Phytonix do?
- Phytonix is an industrial biotechnology company that uses genetically engineered cyanobacteria and synthetic biology to convert carbon dioxide emissions and sunlight into sustainable chemicals and fuels, starting with n-butanol as a drop-in gasoline replacement and industrial chemical. It targets the global n-butanol chemical market and co-locates its production with industrial CO2 emitters.
- Who founded Phytonix?
- Phytonix was founded by Bruce Dannenberg.
- Who are Phytonix's investors?
- Phytonix's investors include Keiretsu Forum.
- How much funding has Phytonix raised?
- Phytonix has disclosed $3.1M raised across 2 of its 4 known rounds.
- Where is Phytonix headquartered?
- Phytonix is headquartered in Black Mountain, US.